ClinicalTrials.gg
Status unknownNCT02471729DENRENICUpdated Oct 19, 2016

Effect at 6 Months of Renal Denervation in Chronic Heart Failure d'Insuffisance Cardiaque

A Phase 1/2 interventional study of EnligHTN™ Renal Denervation System in Chronic Heart Failure, sponsored by Institute Arnault Tzanck, France. Status unknown at 1 site in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2016-10-19.

Sponsored by Institute Arnault Tzanck, France · Phase 1/2, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Oct 2016), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Management of chronic heart failure (CHF) is a major public health problem. It is associated with high mortality, frequent hospitalization and represents a large cost to the health care system. Both pharmacological and non-pharmacological intervention haven't shown to be effective in reducing morbidity and mortality of these patients when able to modulate the activity of neuro-hormonal systems among them the sympathetic nervous system. Recent data have emphasized the potential role of sympathetic renal denervation in patient with hypertension. CHF per se but even more CHF associated with comorbity lead to significant increase level of sympathetic tone. This is largely induced by autonomic dysfunction such as chemo or baroflex abnormalities. These patients usually suffer from conditions which do not allow upgrading and adapting drugs to their sympathetic condition. Hence CHF patient with chronic kidney disease, anemia or both have markedly high sympathetic activity and cannot be exposed to higher level of RAS Blockers or beta blocker due to their renal dysfunction, they thus remain with an elevated sympathetic activity worsening symptoms and prognosis. Chronic heart failure affects around 100 million people worldwild imposing a significant burden on health care system throughout the world. Even though symptoms are improved by heart failure therapy, they remain significantly disabling for many patients. Chronic over activation of the sympathetic nervous system is a major component of heart failure and involves efferent and afferent pathways between brain and many organs. A new therapy directly targeting nerve traffic-renal artery denervation- has been shown to be effective in drug resistant hypertension, with an average drop in blood pressure of 33/12 mm hg.

The cardiologists team of the private hospital Arnault Tzanck is willing therefore to conduct a study in 12 patients with chronic systolic heart failure undergoing bilateral renal denervation with an intensive protocol of observation and assessment compring a 3 day hospital stay post procedure 3 and 6 months of regular outpatient follow-up.

Read the detailed description

Renal denervation is a new interventional cardiology technique that involves using a catheter and a femoral artery, inserting an RF probe that will destroy the nerve fibers in contact with the wall of the renal artery with a very small electric current.

The method utilizes the energy emitted by a miniaturized device positioned at the end of a catheter. This catheter is positioned in the arteries going to the kidneys.

Sympathetic overactivation, is reduced by renal denervation in drug-resistant hypertension. Several studies conducted in patients without heart failure showed that renal denervation reduces left ventricular hypertrophy beyond its only effect on blood pressure.

Chronic over activation of the sympathetic nervous system is a major component of heart failure and involves efferent and afferent pathways between brain and many organs.

The purpose of this Clinical investigation is to evaluate the safety and performance of the EnligHTN™ Renal Denervation System in the treatment of patients with chronique heart failure.

All patients will be on stable maximal tolerated pharmacological therapy for HFC prior to denervation.

After the procedure all patients will be monitored as inpatients for 3 days so that hemodynamic disturbances could be identified. Baseline measurements, including BNP, echo Doppler VO2 and six minutes walk test will be repeated before discharge from hospital.

After discharge patients will be followed up weekly for 4 weeks and then after 3 and 6 months. At the end of the study, bnp, echo Doppler Vo2 and six minutes walk test will be repeated, they also will be asked to categorize themselves as feeling worse, the same, or better in comparison to their preprocedural state.

02

Conditions studied

  • Chronic Heart Failure

Keywords

  • Cardio-Renal Syndrome
  • Chronic Heart Failure
  • Renal Denervation
  • Sympathetic activation
  • Heart Failure
  • Cardiovascular Diseases
  • Heart Diseases
03

In context

Cardio-Renal Syndrome

85 studies on the registry are indexed under Cardio-Renal Syndrome; 20 are open to participants now.

This study's planned enrollment of 12 is below the median of 50 across 55 interventional studies indexed under Cardio-Renal Syndrome.

Browse Cardio-Renal Syndrome studies →

Lead sponsor

Institute Arnault Tzanck, France is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Stable chronic heart failure
  • III-IV
  • LV EF \<35 assessed by ultrasound
  • EGFR> 45ml / min / 1.73m2
  • Optimal therapeutic treatment
  • IMC : 17-24

Exclusion criteria

Exclusion Criteria:

  • significant renovascular abnormalities such as renal artery stenosis> 30%.
  • renal angioplasty history, renal denervation, stent placement
  • hemodynamically significant valvular heart disease
  • an active systemic infection.
  • renal artery of \<4 mm.
  • coagulation abnormalities.
  • kidney transplant or is waiting for a kidney transplant.
  • of less than 12 months (seatle score).
  • femoral-iliac atherosclerotic
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Renal Denervation

    patients with chronique heart failure will undergo EnligHTN™ Renal Denervation System as a complementary treatment of their therapy

    Device: EnligHTN™ Renal Denervation System

Interventions

  • DeviceEnligHTN™ Renal Denervation System

    The renal nerve ablation will be performed according to the EnligHTN™ Renal Denervation System Instructions for Use. This system has the CE mark and is marketed in Europe and manufactured in France. The ablation catheter is indicated for use in renal denervation procedures for the treatment of hypertension.

    Also known as: EnligHTN™ Renal Artery Ablation Catheter, EnligHTN™ RF Generator, EnligHTN™ Guiding Catheter

06

What researchers measure

Primary outcomes

  1. Significant improvement of the 6 minutes walk test

    The primary efficacy end point is the assessment at 6 months post renal denervation of the improvement in symptomatology as BNP level or VO2 max or pharmacological therapy from baseline

    Time frame: 6 months

Secondary outcomes

  1. Incidence of adverse events

    Assessment of renovascular safety as measured by new renal artery stenosis or aneurysm at the site of ablation Renal function change based on eGFR

    Time frame: 5 months

  2. Quality of life evaluated by EQ-5D. 1

    Time frame: before intervention and after 6 months

07

Study locations

1 site
  • Clinique Plein Ciel
    Mougins, Alpes Maritimes 06254, France
    • Jean Louis LLORET, MD · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2017, a primary completion of Sep 2017 and a completion of Jan 2018. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2015
First posted
Jun 15, 2015
Start
Jan 2017
Primary completionEst.
Sep 2017
CompletionEst.
Jan 2018
Last update
Oct 19, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 19, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02471729
Lead sponsor
Institute Arnault Tzanck, France
Responsible party
Sponsor
First posted
Jun 15, 2015
Start date
Jan 2017
Primary completion
Sep 2017 (estimated)
Completion
Jan 2018 (estimated)
Last update
Oct 19, 2016

Study contacts

Jean Louis LLORET, MD
Contact
jl.lloret@tzanck.org
33 (0)4.97.16.65.17
Jean Louis LLORET, MD
principal investigator · Private hospital Mougins Arnault Tzanck

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion